02197.HK

Aug 26, 2026, 01:07 UTC

Clover Biopharmaceuticals reported interim results for the six months ended June 2026, turning a profit of 955 million yuan from a loss of 101 million yuan a year earlier, mainly due to a one-time accounting gain of about 1.087 billion yuan from the GAVI settlement agreement.